The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)

This real-world study (called MORNING) investigates whether combining a liver-directed procedure called TACE (where chemotherapy is delivered directly into the blood vessel feeding a liver tumor) with an immunotherapy drug (AK104) before surgery improves outcomes for people with resectable liver cancer at high risk of recurrence. **You may be eligible if...** - You are between 18 and 75 years old - You have liver cancer (hepatocellular carcinoma) at an early or intermediate stage (BCLC A or B) suitable for surgical removal - You have not received any prior treatment for your liver cancer - Your cancer has at least one high-risk feature for recurrence: multiple tumors, a single tumor larger than 5 cm, elevated AFP blood marker (above 400), or specific MRI findings suggesting vascular invasion - Your liver function and blood counts are adequate **You may NOT be eligible if...** - You have already received treatment for liver cancer - Your liver function or overall health is poor - Your cancer is not resectable Talk to your doctor to see if this trial is right for you.